AGEN
Agenus Inc

12,479
Mkt Cap
$99.3M
Volume
432,822.00
52W High
$7.34
52W Low
$1.38
PE Ratio
-1.37
AGEN Fundamentals
Price
$3.05
Prev Close
$2.92
Open
$2.92
50D MA
$3.45
Beta
1.91
Avg. Volume
924,762.35
EPS (Annual)
-$10.59
P/B
-0.35
Rev/Employee
$327,414.56
$469.71
Loading...
Loading...
News
all
press releases
Agenus to Present New Data at AACR-IO Exploring Systemic and Tumor Inflammation Biomarkers with BOT/BAL in Immunologically Cold Tumors
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced that new translational and clinical biomarker analyses from its botensilimab (BOT) immunotherapy program have been accepted...
Business Wire·9d ago
News Placeholder
More News
News Placeholder
Agenus Inc. (NASDAQ:AGEN) Given Consensus Recommendation of "Hold" by Brokerages
Agenus Inc. (NASDAQ:AGEN - Get Free Report) has earned an average recommendation of "Hold" from the five analysts that are currently covering the company, MarketBeat Ratings reports. One analyst has...
MarketBeat·13d ago
News Placeholder
Agenus Webcast: Zydus Manufacturing Deal Closes, France Access Expands, Phase 3 BATMAN Nears Launch
Agenus (NASDAQ:AGEN) used its first 2026 stakeholder webcast to outline operational and clinical priorities tied to its botensilimab/balstilimab (BOT/BAL) immunotherapy program, highlighting a...
MarketBeat·20d ago
News Placeholder
Agenus Expands Medical Affairs Infrastructure to Support Increasing Physician Requests for Authorized Access to Botensilimab Plus Balstilimab
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the expansion of its global Medical Affairs infrastructure and early-access support capabilities in response to...
Business Wire·28d ago
News Placeholder
Agenus to Host First 2026 Stakeholder Webcast
Agenus Inc. (Agenus) (Nasdaq: AGEN), a leader in immuno-oncology, today announced it will host its first Stakeholder Webcast of 2026, Access to Acceleration: Agenus Global Momentum Entering 2026 on...
Business Wire·28d ago
News Placeholder
Agenus Inc. (NASDAQ:AGEN) Sees Significant Increase in Short Interest
Agenus Inc. (NASDAQ:AGEN - Get Free Report) was the target of a large increase in short interest in December. As of December 31st, there was short interest totaling 3,399,217 shares, an increase of...
MarketBeat·30d ago
News Placeholder
FY2030 Earnings Estimate for Agenus Issued By HC Wainwright
Agenus Inc. (NASDAQ:AGEN - Free Report) - HC Wainwright issued their FY2030 earnings estimates for shares of Agenus in a research note issued on Thursday, January 15th. HC Wainwright analyst E...
MarketBeat·1mo ago
News Placeholder
Zydus Lifesciences Limited completes the acquisition of Agenus Inc.'s biologics manufacturing facilities, launches Zylidac Bio LLC in the U.S.
Zydus Lifesciences Limited completes the acquisition of Agenus Inc.'s biologics manufacturing facilities, launches Zylidac Bio LLC in the U.S. Zydus Lifesciences Limited completes the acquisition of...
PR Newswire·1mo ago
News Placeholder
Agenus Announces Closing of $141M Strategic Collaboration with Zydus Lifesciences to Advance BOT+BAL and Strengthen U.S. Manufacturing Readiness
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the closing of its previously disclosed strategic collaboration with Zydus Lifesciences Ltd. The agreement is...
Business Wire·1mo ago
News Placeholder
Agenus (AGEN) Upgraded to Buy: What Does It Mean for the Stock?
Agenus (AGEN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·1mo ago
<
1
2
...
>

Latest AGEN News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.